• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Ticagrelor Market Analysis

    ID: MRFR/Pharma/0324-CR
    101 Pages
    Kinjoll Dey
    July 2019

    Ticagrelor Market Research Report Information by Dosage (Mg) (90 MG and 60 MG), Route of Administration (Oral and Nasogastric Tube), Application (Acute Coronary Syndrome and Heart Surgeries (Angioplasty, Stent Placement and Coronary Artery Bypass Graft)) End User (Hospitals and Clinics and Ambulatory Centers) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast ti...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Ticagrelor Market Infographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Market Analysis

    In-depth Analysis of Ticagrelor Market Industry Landscape

    The trajectory of market growth for ticagrelor is significantly influenced by the increasing aging population, particularly in the Asia-Pacific region and other developing nations. The aging demographic is more susceptible to chronic ailments such as arthritis, kidney diseases, and cardiovascular diseases, thus acting as a catalyst for the expansion of the market. This demographic shift is particularly pronounced in China, where, according to the China National Committee on Aging, the number of individuals aged 60 and above reached 185 million in 2014, constituting 15.7% of the population. Projections suggest that this figure is anticipated to surge to 487 million by 2053, representing 36.5% of the population. The growing geriatric population is a major driving force behind the market growth in the Asia-Pacific region and similar trends are observed in other developing nations. Globally, data from the United Nations' World Population Prospects reveals that approximately 962 million individuals aged 60 and above were present worldwide as of 2017, constituting about 13% of the global population. The World Health Organization (WHO) estimates that this demographic segment will nearly double from 12% to 22% by the year 2050. In the United States, it is projected that more than 20% of the total population will be aged 65 or over by 2030. Similarly, the United Nations predicts that Asia will house around 857,040 individuals aged 60 and above by 2050. This exponential rise in the older population is directly correlated with the ticagrelor market, as the elderly are more susceptible to injuries and various health conditions such as gastrointestinal problems, orthopedic diseases, and other ailments stemming from compromised immunity. Consequently, this demographic shift increases the frequency of hospital visits among the elderly, contributing to the demand for medications like ticagrelor. the expanding aging population, particularly in regions like Asia-Pacific, is a pivotal factor steering the growth of the ticagrelor market. The prevalence of chronic diseases among the elderly, coupled with the projected surge in the aging demographic globally, underscores the significance of pharmaceutical interventions like ticagrelor. As the world witnesses a substantial increase in the older population, the demand for treatments addressing the unique healthcare needs of this demographic is expected to escalate, positioning ticagrelor as a crucial player in addressing the health challenges associated with an aging population.

    Market Summary

    As per Market Research Future Analysis, the Ticagrelor Market is projected to grow at a CAGR of 6.4%, reaching USD 3.32 Billion by 2032. Ticagrelor is an antiplatelet drug that reduces platelet aggregation and prevents blood clots, primarily used in acute coronary syndrome (ACS). The market growth is driven by an increasing cardiovascular disease prevalence, particularly among the aging population, and advancements in product development. However, significant bleeding risks associated with Ticagrelor may hinder market expansion. The market is segmented by product type (0 mg and 60 mg Tablets), application (Clinic Pharmacies, Retail Pharmacies, Online Pharmacies), end-users (hospitals and clinics), and region (Americas, Europe, Asia-Pacific, Middle East, and Africa). The Americas is expected to dominate the market due to a high prevalence of chronic diseases and advanced healthcare infrastructure.

    Key Market Trends & Highlights

    The Ticagrelor Market is characterized by several key trends and opportunities.

    • Market Size: USD 3.32 Billion by 2032; CAGR: 6.4%
    • Major Opportunities: New product launches and R&D initiatives.
    • Market Restraints: Side effects like bleeding and dyspnea may limit usage.
    • Regional Growth: Asia-Pacific is the fastest-growing market due to rising disposable incomes.

    Market Size & Forecast

    Market Size USD 3.32 Billion by 2032
    CAGR 6.4%
    Largest Regional Market Americas
    Fastest Growing Region Asia-Pacific

    Major Players

    AstraZeneca, Eli Lilly, Ingelheim, Alexion, Roche, Amgen, Boehringer, Pfizer, Merck, GSK

    Market Trends

    Regional Analysis as per the Market Forecast. Market Competitive Landscape Developments in Market Value

    This report highlights the growth aspects of the Ticagrelor Market Revenue. Along with that, this report also intends to put up the competitive landscape and recent developments on the table to explain this global Atorvastatin API Market position.

    The ongoing evolution of the cardiovascular treatment landscape suggests that Ticagrelor is increasingly recognized for its role in improving patient outcomes, particularly in high-risk populations.

    U.S. Food and Drug Administration (FDA)

    Ticagrelor Market Market Drivers

    Market Growth Projections

    The Global Ticagrelor Market Industry is projected to experience robust growth over the coming years. With an estimated market value of 0.97 USD Billion in 2024, the industry is on a trajectory to reach 4.0 USD Billion by 2035. This growth is underpinned by a compound annual growth rate of 13.73 percent from 2025 to 2035. Such projections indicate a strong demand for Ticagrelor, driven by factors such as increasing cardiovascular disease prevalence, advancements in drug formulations, and enhanced healthcare access in emerging markets. These metrics highlight the potential for sustained growth in the Global Ticagrelor Market Industry.

    Growing Awareness and Education

    The increasing awareness and education regarding the importance of antiplatelet therapy contribute significantly to the Global Ticagrelor Market Industry. Healthcare providers are actively promoting the benefits of Ticagrelor in preventing cardiovascular events, leading to higher prescription rates. Initiatives by organizations such as the American Heart Association emphasize the need for effective treatment options, thereby influencing patient choices. This heightened awareness is likely to drive market growth, as more patients seek out Ticagrelor as a viable treatment option. The anticipated compound annual growth rate of 13.73 percent from 2025 to 2035 further illustrates this trend.

    Advancements in Drug Formulations

    Innovations in drug formulations and delivery mechanisms are propelling the Global Ticagrelor Market Industry forward. Recent advancements have enhanced the efficacy and safety profiles of Ticagrelor, making it a preferred choice among healthcare professionals. For example, the development of fixed-dose combinations with other antiplatelet agents has shown promising results in clinical trials. These innovations not only improve patient adherence but also expand the therapeutic applications of Ticagrelor. As a result, the market is anticipated to experience substantial growth, potentially reaching 4.0 USD Billion by 2035, driven by these advancements.

    Emerging Markets and Accessibility

    The expansion of healthcare infrastructure in emerging markets is a crucial driver for the Global Ticagrelor Market Industry. As countries invest in improving healthcare access, the availability of Ticagrelor is likely to increase, reaching a broader patient population. For example, nations in Asia and Africa are witnessing significant improvements in healthcare delivery systems, which facilitate the distribution of essential medications. This trend is expected to contribute to the overall market growth, as more patients gain access to effective antiplatelet therapies. The Global Ticagrelor Market Industry is poised to benefit from these developments, enhancing its reach and impact.

    Increasing Cardiovascular Diseases

    The rising prevalence of cardiovascular diseases globally is a primary driver for the Global Ticagrelor Market Industry. As heart-related ailments continue to escalate, the demand for effective antiplatelet therapies like Ticagrelor is expected to grow. For instance, the World Health Organization indicates that cardiovascular diseases account for approximately 32 percent of all global deaths. This alarming statistic underscores the urgent need for effective treatment options. Consequently, the Global Ticagrelor Market Industry is projected to reach 0.97 USD Billion in 2024, reflecting a significant response to this health crisis.

    Regulatory Approvals and Guidelines

    The role of regulatory approvals and clinical guidelines cannot be understated in the Global Ticagrelor Market Industry. Regulatory bodies are increasingly recognizing the efficacy of Ticagrelor, leading to expedited approvals for new indications. For instance, recent updates in clinical guidelines recommend Ticagrelor as a first-line treatment for certain patient populations. Such endorsements not only enhance the drug's credibility but also encourage healthcare providers to prescribe it more frequently. This regulatory support is expected to bolster market growth, as the industry adapts to evolving clinical practices and guidelines.

    Market Segment Insights

    Regional Insights

    Key Companies in the Ticagrelor Market market include

    Industry Developments

      • September 02, 2019, the Strs Ohio (the US), a main worldwide institutional financial backer, reported the securing of another stake in Phase Bio Pharmaceuticals Inc. (the US), a clinical-stage biopharmaceutical organization. 
      • haseBio centers around the turn of events and commercialization of novel treatments and medications, for example, an inversion specialist for the antiplatelet drug ticagrelor

    Future Outlook

    Ticagrelor Market Future Outlook

    The Global Ticagrelor Market is poised for growth at a 13.73% CAGR from 2024 to 2035, driven by increasing cardiovascular disease prevalence and advancements in drug formulations.

    New opportunities lie in:

    • Develop novel Ticagrelor combinations to enhance efficacy and reduce side effects.
    • Expand into emerging markets with tailored marketing strategies and local partnerships.
    • Invest in digital health solutions to improve patient adherence and monitoring.

    By 2035, the Ticagrelor Market is expected to achieve substantial growth, reflecting evolving healthcare needs and innovations.

    Market Segmentation

    Report Overview

    • Market Overview
    • COVID 19 Analysis
    • Market dynamics
    • Market Trends Segment Overview
    • Regional Analysis as per the Market Forecast.
    • Market Competitive Landscape
    • Developments in Market Value

    Recent Developments

    • September 02, 2019, the Strs Ohio (the US), a main worldwide institutional financial backer, reported the securing of another stake in Phase Bio Pharmaceuticals Inc. (the US), a clinical-stage biopharmaceutical organization. 
    • haseBio centers around the turn of events and commercialization of novel treatments and medications, for example, an inversion specialist for the antiplatelet drug ticagrelor

    Competitive Landscape

    • AstraZeneca, Eli Lilly
    • Ingelheim
    • Alexion
    • Roche
    • Amgen
    • Boehringer
    • Pfizer
    • Merck
    • GSK
    • Boehringer
    • Amgen

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 NA (USD Billion)
    Market Size 2024 NA (USD Billion)
    Market Size 2032 3.32 (USD Billion)
    Compound Annual Growth Rate (CAGR) 6.4 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   AstraZeneca, PLC.
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers ·  Increasing cardiovascular rate ·  Rise in the older population

    Market Highlights

    Author

    Kinjoll Dey
    Research Analyst Level I

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM
    View All

    FAQs

    At what CAGR is the ticagrelor market projected to grow in the forecast period (2023-2030)?

    Ticagrelor market projected to grow at approximately 6.4% CAGR during the assessment period (2023-2032).

    How much is the ticagrelor market worth in the future?

    The valuation of the ticagrelor market is estimated to increase to USD 3.32 Billion by the end of 2032.

    What are the major tailwinds pushing the growth of the ticagrelor market?

    Large patient pool suffering from heart problems and increasing product development, commercialization, and improving funding for R&D by the market players are major tailwinds pushing the growth of the ticagrelor market.

    Which region holds the largest share in the ticagrelor market?

    North America holds the largest share in the ticagrelor market, followed by Europe and the Asia Pacific, respectively.

    Who are the top players in the ticagrelor market?

    AstraZeneca, Eli Lilly, Boehringer, Ingelheim, Pfizer, Amgen, Merck, Roche, GSK, Boehringer, Alexion, and Amgen, are some of the top players operating in the global ticagrelor market.

    1. Report Prologue
    2. Introduction
      1. Definition 14
      2. Scope of the Study 14
      3. Research Objective 14
      4. Assumptions & Limitations 14
        1. Assumptions 14
        2. Limitations 14
        3. Market Structure 14
    3. Research Methodology
      1. Primary Research Methodology 16
      2. Secondary Research Methodology 18
      3. Market Size Estimation 19
      4. Forecast Model 19
    4. Market Dynamics
      1. Drivers 21
        1. Rising Cardiovascular Disorders 21
        2. Increasing Geriatric Population 22
      2. Restraints 22
        1. High Bleeding Complications 22
      3. Opportunities 22
        1. Exploring New Applications 22
    5. Market Factor Analysis
      1. Porter’s Five Forces Model 24
        1. Bargaining Power of Suppliers 24
        2. Bargaining Power of Buyers 25
        3. Threat of New Entrants 25
        4. Threat of Substitutes 25
        5. Intensity of Rivalry 25
      2. Value Chain Analysis 26
        1. R&D 26
        2. Manufacturing 26
        3. Distribution & Sales 26
        4. Post-Sales Monitoring 26
      3. Demand & Supply: Gap Analysis 27
      4. Pricing Analysis 27
      5. Investment Opportunities 27
      6. Macroeconomic Indicators 27
      7. Pipeline Analysis 28
    6. The Global Ticagrelor Market, by Dosage (Mg)
      1. Introduction 30
      2. 90 MG 31
      3. 60 MG 31
    7. The Ticagrelor Market, by Route of Administration
      1. Introduction 33
      2. Oral 34
      3. Nasogastric Tube 34
    8. The Ticagrelor Market, by Application
      1. Introduction 36
      2. Acute Coronary Syndrome 37
      3. Heart Surgeries 37
        1. Angioplasty 38
        2. Stent Placement 38
        3. Coronary Artery Bypass Graft 39
    9. The Ticagrelor Market, by End User
      1. Introduction 41
      2. Hospitals and Clinics 42
      3. Ambulatory Centers 42
    10. The Global Ticagrelor Market, by Region
      1. Introduction 44
      2. Americas 46
    11. The Ticagrelor Market, by Route of Administration
    12. The Ticagrelor Market, by Application
    13. The Ticagrelor Market, by End User
      1. North America 48
        1. US 50
    14. The Ticagrelor Market, by Route of Administration
    15. The Ticagrelor Market, by Application
      1. Canada 52
    16. The Ticagrelor Market, by Route of Administration
      1. South America 54
      2. Europe 56
    17. The Ticagrelor Market, by Route of Administration
    18. The Ticagrelor Market, by End User
      1. Western Europe 58
    19. The Ticagrelor Market, by Route of Administration
      1. Germany 60
    20. The Ticagrelor Market, by Route of Administration
      1. UK 62
    21. The Ticagrelor Market, by Route of Administration
    22. The Ticagrelor Market, by End User
      1. France 63
        1. Italy 65
    23. The Ticagrelor Market, by Application
      1. Spain 67
    24. The Ticagrelor Market, by Application
      1. Rest of Western Europe 68
        1. Eastern Europe 70
      2. Asia-Pacific 72
        1. Japan 74
        2. China 76
        3. India 77
        4. Australia 79
        5. South Korea 81
        6. Rest of Asia-Pacific 82
      3. Rest of the World 85
        1. Middle East 87
        2. Africa 89
        3. Other Countries 90
    25. Company Landscape
      1. Introduction 94
    26. Company Profiles
      1. AstraZeneca, PLC 96
        1. Company Overview 96
        2. Financial Overview 96
        3. Products Offering 97
        4. Key Developments 97
        5. SWOT Analysis 97
        6. Key Strategy 97
    27. Appendix
      1. Discussion Blue Print 99
      2. References 100
    28. List of Tables and Figures
      1. 14 List of Tables
      2. TABLE 1 PRIMARY INTERVIEWS 17
      3. TABLE 2 PIPELINE PRODUCTS 28
      4. TABLE 3 GLOBAL TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 30
      5. TABLE 4 GLOBAL TICAGRELOR MARKET FOR 90 MG, BY REGION, 2023–2030 (USD MILLION) 31
      6. TABLE 5 GLOBAL TICAGRELOR MARKET FOR 60 MG, BY REGION, 2023–2030 (USD MILLION) 31
      7. TABLE 6 GLOBAL TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 33
      8. TABLE 7 GLOBAL TICAGRELOR MARKET FOR ORAL, BY REGION, 2023–2030 (USD MILLION) 34
      9. TABLE 8 GLOBAL TICAGRELOR MARKET FOR NASOGASTRIC TUBE, BY REGION, 2023–2030 (USD MILLION) 34
      10. TABLE 9 GLOBAL TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 36
      11. TABLE 10 GLOBAL TICAGRELOR MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2023–2030 (USD MILLION) 37
      12. TABLE 11 GLOBAL TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 37
      13. TABLE 12 GLOBAL TICAGRELOR MARKET FOR HEART SURGERIES, BY REGION 2023-2030 (USD MILLION) 38
      14. TABLE 13 GLOBAL TICAGRELOR MARKET FOR ANGIOPLASTY, BY REGION, 2023–2030 (USD MILLION) 38
      15. TABLE 14 GLOBAL TICAGRELOR MARKET FOR STENT PLACEMENT, BY REGION, 2023–2030 (USD MILLION) 38
      16. TABLE 15 GLOBAL TICAGRELOR MARKET FOR CORONARY ARTERY BYPASS GRAFT-, BY REGION, 2023–2030 (USD MILLION) 39
      17. TABLE 16 GLOBAL TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 41
      18. TABLE 17 GLOBAL TICAGRELOR MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2023–2030 (USD MILLION) 42
      19. TABLE 18 GLOBAL TICAGRELOR MARKET FOR AMBULATORY CENTERS, BY REGION, 2023–2030 (USD MILLION) 42
      20. TABLE 19 GLOBAL TICAGRELOR MARKET, BY REGION 2023-2030 (USD MILLION) 45
      21. TABLE 20 AMERICAS TICAGRELOR MARKET, BY REGION 2023-2030 (USD MILLION) 46
      22. TABLE 21 AMERICAS TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 46
      23. TABLE 22 AMERICAS TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 47
      24. TABLE 23 AMERICAS TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 47
      25. TABLE 24 AMERICAS TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 47
      26. TABLE 25 AMERICAS TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 48
      27. TABLE 26 NORTH AMERICA TICAGRELOR MARKET, BY COUNTRY 2023-2030 (USD MILLION) 48
      28. TABLE 27 NORTH AMERICA TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 49
      29. TABLE 28 NORTH AMERICA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 49
      30. TABLE 29 NORTH AMERICA TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 49
      31. TABLE 30 NORTH AMERICA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 49
      32. TABLE 31 NORTH AMERICA TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 50
      33. TABLE 32 US TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 50
      34. TABLE 33 US TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 50
      35. TABLE 34 US TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 51
      36. TABLE 35 US TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 51
      37. TABLE 36 US TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 51
      38. TABLE 37 CANADA TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 52
      39. TABLE 38 CANADA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 52
      40. TABLE 39 CANADA TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 52
      41. TABLE 40 CANADA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 53
      42. TABLE 41 CANADA TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 53
      43. TABLE 42 SOUTH AMERICA TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 54
      44. TABLE 43 SOUTH AMERICA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 54
      45. TABLE 44 SOUTH AMERICA TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 54
      46. TABLE 45 SOUTH AMERICA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 55
      47. TABLE 46 SOUTH AMERICA TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 55
      48. TABLE 47 EUROPE TICAGRELOR MARKET, BY REGION 2023-2030 (USD MILLION) 56
      49. TABLE 48 EUROPE TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 56
      50. TABLE 49 EUROPE TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 57
      51. TABLE 50 EUROPE TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 57
      52. TABLE 51 EUROPE TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 57
      53. TABLE 52 EUROPE TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 58
      54. TABLE 53 WESTERN EUROPE TICAGRELOR MARKET, BY COUNTRY 2023-2030 (USD MILLION) 58
      55. TABLE 54 WESTERN EUROPE TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 59
      56. TABLE 55 WESTERN EUROPE TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 59
      57. TABLE 56 WESTERN EUROPE TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 59
      58. TABLE 57 WESTERN EUROPE TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 59
      59. TABLE 58 WESTERN EUROPE TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 60
      60. TABLE 59 GERMANY TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 60
      61. TABLE 60 GERMANY TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 60
      62. TABLE 61 GERMANY TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 61
      63. TABLE 62 GERMANY TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 61
      64. TABLE 63 GERMANY TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 61
      65. TABLE 64 UK TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 62
      66. TABLE 65 UK TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 62
      67. TABLE 66 UK TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 62
      68. TABLE 67 UK TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 63
      69. TABLE 68 UK TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 63
      70. TABLE 69 FRANCE TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 63
      71. TABLE 70 FRANCE TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 64
      72. TABLE 71 FRANCE TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 64
      73. TABLE 72 FRANCE TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 64
      74. TABLE 73 FRANCE TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 65
      75. TABLE 74 ITALY TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 65
      76. TABLE 75 ITALY TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 65
      77. TABLE 76 ITALY TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 66
      78. TABLE 77 ITALY TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 66
      79. TABLE 78 ITALY TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 66
      80. TABLE 79 SPAIN TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 67
      81. TABLE 80 SPAIN TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 67
      82. TABLE 81 SPAIN TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 67
      83. TABLE 82 SPAIN TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 68
      84. TABLE 83 SPAIN TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 68
      85. TABLE 84 REST OF WESTERN EUROPE TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 68
      86. TABLE 85 REST OF WESTERN EUROPE TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 69
      87. TABLE 86 REST OF WESTERN EUROPE TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 69
      88. TABLE 87 REST OF WESTERN EUROPE TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 69
      89. TABLE 88 REST OF WESTERN EUROPE TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 70
      90. TABLE 89 EASTERN EUROPE TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 70
      91. TABLE 90 EASTERN EUROPE TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 70
      92. TABLE 91 EASTERN EUROPE TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 71
      93. TABLE 92 EASTERN EUROPE TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 71
      94. TABLE 93 EASTERN EUROPE TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 71
      95. TABLE 94 ASIA-PACIFIC TICAGRELOR MARKET, BY COUNTRY 2023-2030 (USD MILLION) 72
      96. TABLE 95 ASIA-PACIFIC TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 72
      97. TABLE 96 ASIA-PACIFIC TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 73
      98. TABLE 97 ASIA-PACIFIC TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 73
      99. TABLE 98 ASIA-PACIFIC TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 73
      100. TABLE 99 ASIA-PACIFIC TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 74
      101. TABLE 100 JAPAN TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 74
      102. TABLE 101 JAPAN TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 74
      103. TABLE 102 JAPAN TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 75
      104. TABLE 103 JAPAN TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 75
      105. TABLE 104 JAPAN TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 75
      106. TABLE 105 CHINA TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 76
      107. TABLE 106 CHINA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 76
      108. TABLE 107 CHINA TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 76
      109. TABLE 108 CHINA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 77
      110. TABLE 109 CHINA TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 77
      111. TABLE 110 INDIA TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 77
      112. TABLE 111 INDIA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 78
      113. TABLE 112 INDIA TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 78
      114. TABLE 113 INDIA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 78
      115. TABLE 114 INDIA TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 79
      116. TABLE 115 AUSTRALIA TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 79
      117. TABLE 116 AUSTRALIA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 79
      118. TABLE 117 AUSTRALIA TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 80
      119. TABLE 118 AUSTRALIA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 80
      120. TABLE 119 AUSTRALIA TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 80
      121. TABLE 120 SOUTH KOREA TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 81
      122. TABLE 121 SOUTH KOREA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 81
      123. TABLE 122 SOUTH KOREA TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 81
      124. TABLE 123 SOUTH KOREA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 82
      125. TABLE 124 SOUTH KOREA TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 82
      126. TABLE 125 REST OF ASIA-PACIFIC TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 82
      127. TABLE 126 REST OF ASIA-PACIFIC TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 83
      128. TABLE 127 REST OF ASIA-PACIFIC TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 83
      129. TABLE 128 REST OF ASIA-PACIFIC TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 83
      130. TABLE 129 REST OF ASIA-PACIFIC TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 84
      131. TABLE 130 REST OF THE WORLDTICAGRELOR MARKET, BY REGION 2023-2030 (USD MILLION) 85
      132. TABLE 131 REST OF THE WORLDTICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 85
      133. TABLE 132 REST OF THE WORLDTICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 86
      134. TABLE 133 REST OF THE WORLDTICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 86
      135. TABLE 134 REST OF THE WORLDTICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 86
      136. TABLE 135 REST OF THE WORLDTICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 87
      137. TABLE 136 MIDDLE EAST TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 87
      138. TABLE 137 MIDDLE EAST TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 87
      139. TABLE 138 MIDDLE EAST TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 88
      140. TABLE 139 MIDDLE EAST TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 88
      141. TABLE 140 MIDDLE EAST TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 88
      142. TABLE 141 AFRICA TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 89
      143. TABLE 142 AFRICA TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 89
      144. TABLE 143 AFRICA TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 89
      145. TABLE 144 AFRICA TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 90
      146. TABLE 145 AFRICA TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 90
      147. TABLE 146 OTHER COUNTRIES TICAGRELOR MARKET, BY DOSAGE (MG) 2023-2030 (USD MILLION) 90
      148. TABLE 147 OTHER COUNTRIES TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023-2030 (USD MILLION) 91
      149. TABLE 148 OTHER COUNTRIES TICAGRELOR MARKET, BY APPLICATION 2023-2030 (USD MILLION) 91
      150. TABLE 149 OTHER COUNTRIES TICAGRELOR MARKET FOR HEART SURGERIES, BY TYPE 2023-2030 (USD MILLION) 91
      151. TABLE 150 OTHER COUNTRIES TICAGRELOR MARKET, BY END-USER 2023-2030 (USD MILLION) 92 15 List of Figures
      152. FIGURE 1 TOP-DOWN & Bottom-up ApproachES 19
      153. FIGURE 2 MARKET DYNAMICS: GLOBAL TICAGRELOR MARKET 21
      154. FIGURE 3 PORTER’S FIVE FORCES ANALYSIS: GLOBAL TICAGRELOR MARKET 24
      155. FIGURE 4 VALUE CHAIN ANALYSIS OF THE GLOBAL TICAGRELOR MARKET 26
      156. FIGURE 5 GLOBAL TICAGRELOR MARKET, BY DOSAGE (MG) 2023 & 2030 (USD MILLION) 30
      157. FIGURE 6 GLOBAL TICAGRELOR MARKET, BY ROUTE OF ADMINISTRATION 2023 & 2030 (USD MILLION) 33
      158. FIGURE 7 GLOBAL TICAGRELOR MARKET, BY APPLICATION 2023 & 2030 (USD MILLION) 36
      159. FIGURE 8 GLOBAL TICAGRELOR MARKET, FOR HEART SURGERIES BY TYPE 2023 & 2030 (USD MILLION) 37
      160. FIGURE 9 GLOBAL TICAGRELOR MARKET, BY END-USER 2023 & 2030 (USD MILLION) 41
      161. FIGURE 10 GLOBAL TICAGRELOR MARKET, BY REGION 2023 & 2030 (USD MILLION) 45
      162. FIGURE 11 AMERICAS TICAGRELOR MARKET SHARE, BY REGION 2023 (%) 46
      163. FIGURE 12 AMERICAS TICAGRELOR MARKET SHARE, BY COUNTRY 2023 (%) 48
      164. FIGURE 13 EUROPE TICAGRELOR MARKET, BY REGION 2023 (%) 56
      165. FIGURE 14 WESTERN EUROPE TICAGRELOR MARKET, BY COUNTRY 2023 (%) 58
      166. FIGURE 15 ASIA-PACIFIC TICAGRELOR MARKET, BY COUNTRY 2023 (%) 72
      167. FIGURE 16 REST OF THE WORLDTICAGRELOR MARKET, BY REGION 2023(%) 85

    Ticagrelor Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027